Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.46 |
| ▸ | RCE1 | Q9Y256 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | PRNP | P04156 | 1/20 | 0.37 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | NR2E3 | Q9Y5X4 | 1/20 | 0.37 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 2/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7157767 | 0.98 | RXFP1 (0.47) | RXFP1RCE1KDM4EMEN1PRNP | |
| SCHEMBL30779734 | 0.96 | RXFP1 (0.46) | RXFP1RCE1KDM4EMEN1PRNP | |
| SCHEMBL1473182 | 0.77 | RXFP1 (0.65) | RXFP1RCE1KDM4EMEN1PRNP | |
| SCHEMBL5494063 | 0.77 | RXFP1 (0.46) | RXFP1RCE1KDM4EMEN1PRNP | |
| SCHEMBL14357456 | 0.74 | RXFP1 (0.43) | RXFP1RCE1KDM4EMEN1PRNP | |
| SCHEMBL8436464 | 0.67 | RXFP1 (0.51) | RXFP1RCE1KDM4EMEN1PRNP | |
| SCHEMBL14613045 | 0.65 | MEN1 (0.46) | RXFP1RCE1KDM4EMEN1PRNP | |
| SCHEMBL11730375 | 0.61 | ALOX15 (0.41) | MEN1KMT2AALOX15 | |
| SCHEMBL14357457 | 0.60 | KDM4E (0.44) | RXFP1RCE1KDM4EALOX15 | |
| SCHEMBL27284275 | 0.60 | EGFR (0.38) | RXFP1RCE1KDM4EEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117801564-A | Pyrroline disperse dye containing indole group and preparation and application thereof | 沈阳化工研究院有限公司 | 2024-04-02 | — | — | CN | disclosed |
| US-20130118570-A1 | DYE FOR PHOTOELECTRIC CONVERSION, SEMICONDUCTOR ELECTRODE, PHOTOELECTRIC CONVERSION ELEMENT, SOLAR CELL, AND NOVEL PYRROLINE-BASED COMPOUND | NEC CORPORATION (JP) | 2013-05-16 | — | — | US | disclosed |
| US-7915428-B2 | Photorefractive dendron compound, photorefractive dendrimer compound, method of preparing the same, photorefractive device using the same, and method of manufacturing the device | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2011-03-29 | — | — | US | disclosed |
| US-20090223627-A1 | PHOTOREFRACTIVE DENDRON COMPOUND, PHOTOREFRACTIVE DENDRIMER COMPOUND, METHOD OF PREREPARING THE SAME, PHOTOREFRACTIVE DEVICE USING THE SAME, AND METHOD OF MANUFACTURING THE DEVICE | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090223627-A1 | PHOTOREFRACTIVE DENDRON COMPOUND, PHOTOREFRACTIVE DENDRIMER COMPOUND, METHOD OF PREREPARING THE SAME, PHOTOREFRACTIVE DEVICE USING THE SAME, AND METHOD OF MANUFACTURING THE DEVICE | KISS1R, CROCC, DBN1 | RXFP1 412/4885RCE1 1146/4885KDM4E 4384/4885 |
| US-20130118570-A1 | DYE FOR PHOTOELECTRIC CONVERSION, SEMICONDUCTOR ELECTRODE, PHOTOELECTRIC CONVERSION ELEMENT, SOLAR CELL, AND NOVEL PYRROLINE-BASED COMPOUND | SCO2, PYCR1, CRY1 | RXFP1 3674/4885RCE1 2156/4885KDM4E 2371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.